Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
12 déc. 2022 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
06 déc. 2022 07h45 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced the pricing of $500 million in aggregate principal...
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
05 déc. 2022 07h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced that it intends to offer, subject to market conditions...
Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
29 nov. 2022 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA
28 nov. 2022 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
14 nov. 2022 07h00 HE
|
Lantheus Holdings, Inc.
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticalsExpands Lantheus’ portfolio...
Lantheus to Present at the Jefferies London Healthcare Conference
09 nov. 2022 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus Reports Third Quarter 2022 Financial Results
03 nov. 2022 07h00 HE
|
Lantheus Holdings, Inc.
Worldwide revenue of $239.3 million for the third quarter 2022, representing an increase of 134.4% from the prior year period GAAP net income of $61.2 million for the third quarter 2022, compared to...
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time
20 oct. 2022 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on...
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
17 oct. 2022 09h14 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...